SCHEMBL297348

SCHEMBL297348

COc1ccc2c(C)c3n(c(=O)c2c1OC)CCc1cc2c(cc1-3)OCO2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.66
CYP2D6 P10635 5/20 0.50
KMT2A Q03164 3/20 0.50
ACHE P22303 3/20 0.47
P2RX7 Q99572 2/20 0.43
CYP3A4 P08684 7/20 0.43
TSHR P16473 3/20 0.43
EP300 Q09472 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 3/20 0.43
CYP1A2 P05177 3/20 0.43
CHRM1 P11229 2/20 0.43
DRD2 P14416 2/20 0.43
ADRA2B P18089 2/20 0.43
ADRA2C P18825 2/20 0.43
RXRA P19793 2/20 0.43
DRD1 P21728 2/20 0.43
HTR2B P41595 2/20 0.43
HTT P42858 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31472747 0.89 BCHE (0.65) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL31472746 0.89 BCHE (0.65) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL31472748 0.89 BCHE (0.65) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL299042 0.87 BCHE (0.63) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL18037460 0.87 BCHE (0.62) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL18037452 0.86 BCHE (0.61) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL18037465 0.85 BCHE (0.57) BCHECYP2D6KMT2AACHEP2RX7
SCHEMBL18058577 0.85 BCHE (0.57) BCHECYP2D6KMT2AACHECYP3A4
SCHEMBL13071079 0.85 BCHE (0.46) BCHEACHECYP3A4ALDH1A1MAPT
SCHEMBL16884608 0.84 BCHE (0.56) BCHECYP2D6KMT2AACHEP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427460-B1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-26 EP disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2427460-A1 NOVEL ISOQUINOLINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010128061-A1 NOVEL ISOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES CYP3A7, RAB7A, IPO7 BCHE 3051/4885CYP2D6 61/4885KMT2A 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.